

**hVIVO plc**  
**("hVIVO" or the "Company")**

**Appointment of Nominated Adviser and Joint Broker**

hVIVO plc (AIM & Euronext: HVO) the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as Joint Broker with immediate effect.

**For further information please contact:**

**hVIVO plc** +44 (0) 20 7756 1300  
Yamin 'Mo' Khan, Chief Executive Officer  
Stephen Pinkerton, Chief Financial Officer

**Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)** +44 (0) 20 7220 0500  
Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward

**Peel Hunt LLP (Joint Broker)** +44 (0)20 7418 8900  
James Steel, Dr Christopher Golden

**Davy (Euronext Growth Adviser and Joint Broker)** +353 (0) 1 679 6363  
Anthony Farrell, Niall Gilchrist

**Walbrook PR (Financial PR & IR)** +44 (0) 20 7933 8780 or hvivo@walbrookpr.com  
Stephanie Cuthbert / Phillip Marriage / +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /  
Louis Ashe-Jepson +44 (0) 7747 515 393

**Notes to Editors**

**About hVIVO**

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its [FluCamp](#) volunteer screening facilities in London and Manchester.

**Existing Board - AIM Rule 17 Disclosure**

The Company announces the following additional director disclosures pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

**Elaine Sullivan**

In addition to the disclosures made in Elaine Sullivan's announcement of appointment on 24 November 2020, the following directorships are disclosed:

Company	Current, or last 5 years
Carrick Therapeutics Limited	Directorship held in last 5 years, at time of appointment to hVIVO

**Brendan Buckley**

The following directorships were disclosed incorrectly in the Company's Admission Document dated 9 December 2019:

Company	Disclosure
Irish Platform for Patients' Organisations, Science and Industry Company Limited	Directorship held more than 5 years prior to publication of the Admission Document and therefore should not have been disclosed in the Admission Document

**Cathal Friel**

In addition to the disclosures made in the Admission Document dated 9 December 2019, the following directorships are disclosed:

Company	Current, or last 5 years
Amryt Pharma Holdings Limited	Directorship held in last 5 years at time of Admission Document publication
Venn Life Sciences Limited Venn Life Sciences (Germany) GmbH Venn Life Sciences (Ireland) Limited Venn Life Sciences (NI) Limited Venn Life Sciences (Australia) Pty Ltd Venn Life Sciences Inc. Venn Life Sciences Legal Representation B.V Venn Life Sciences ED B.V. Venn Life Sciences (France) SAS Venn Life Sciences B.V.	Current directorship at the time of Admission Document publication

The following directorships were disclosed incorrectly in the Company's Admission Document dated 9 December 2019:

Company	Current, or last 5 years
Amryt Pharma plc	Incorrectly disclosed as a directorship
Fastnet Hydrocarbons Limited Raglan Natural Resources Limited	Directorship held in last 5 years at time of Admission Document publication. These directorships were disclosed as current directorships in the Admission Document
Fitzwilliam Place Capital Limited	Directorship held more than 5 years prior to Admission Document publication and therefore should not have been disclosed in the Admission Document

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.lse.com](http://www.lse.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPQKABQBBKCDCK